Drug Manufacturers - Major

RECENT NEWS
Forbes  Oct 21  Comment 
The discovery and early development phases of pharmaceutical R&D are notoriously challenging.  Success (even marked by regulatory approval, let alone meaningful sales) is a distant vision.  The cost of prosecuting each project is high, and rises...
SeekingAlpha  Oct 18  Comment 
By Vuru: Cardinal Health, Inc. (NYSE:CAH) is an Ohio corporation formed in 1979 with the acquisition of Bailey Drug Co., an Ohio-based wholesaler. CAH is a healthcare services company providing products and services that help pharmacies,...
Wall Street Journal  Oct 17  Comment 
The Ebola outbreak has created an urgency for pharmaceutical companies and health officials to produce drugs to treat the disease.
Wall Street Journal  Oct 17  Comment 
The likely collapse of AbbVie’s $54 billion deal to buy Shire leaves two global drug companies in need of new, independent courses and investors and Wall Street bankers smarting from losses and fees they won’t collect.
Forbes  Oct 16  Comment 
Biologic drugs are a big deal for the pharmaceutical industry right now. Blockbuster chemicals for common conditions like diabetes and hypertension are largely things of the past. We’re getting pretty good at controlling those conditions, and...
Wall Street Journal  Oct 16  Comment 
AbbVie has unceremoniously ditched Shire, pulling the plug on its $54 billion takeover. But the pharmaceutical company needn’t sob for long.
SeekingAlpha  Oct 16  Comment 
By Matthew Smith: While early market trading yesterday seemed to indicate that we might have seen a capitulation moment, the action which took place later in the day ended any hopes of that. We did see another rally off of lows in the afternoon,...
GenEng News  Oct 16  Comment 
The FDA’s Center for Drug Evaluation and Research (CDER) said today it will step up its oversight of drug quality next year through a new “super-office” created for the purpose, with functions and personnel that will be shifted there from...
New York Times  Oct 16  Comment 
The $54 billion takeover of the Irish pharmaceutical company Shire appears to be in jeopardy after the Treasury changed tax rules to discourage companies from reincorporating overseas.




 

The pharmaceutical industry consists of companies that research, develop, market, and distribute drugs for nearly every therapeutic need. Drug sales from the 65 largest pharmaceuticals totaled $606 billion in 2007 and continues to grow.[1]

Commercial drug companies are driven by research and patent protection. Developing a drug requires an enormous amount of investment in technology, materials, and time, and can be a risky venture for the company. However, after a new drug is successfully developed, thoroughly tested, and patented, it may be potentially very lucrative, especially if it addresses a common health problem (such as heart disease or cancer).

Pharmaceutical Industry Trends & Forces

Pipeline Risks

Developing a new drug is a time-consuming and costly endeavor. Hundreds of thousands of candidate compounds must be screened to identify a handful of potential drugs. Even fewer of these candidate drugs are found to be effective at treating a disease. The drug must then pass strict safety standards in several series of clinical trials. According to the Pharmaceutical Research and Manufacturers of America's 2006 Pharmaceutical Industry Profile, developing a new drug and bringing it to the market takes up to 10 to 15 years and on average costs $800 million. ray

The FDA has also become more strict in the approval process. In 2007, the FDA approved 19 new drugs, the lowest number since 1983.[2]

Generic drugs: stiff competition

For a detailed discussion of brand name vs generic medication, see also Brand name vs Generic medications.

Due to Food and Drug Administration (FDA) regulations, pharmaceutical patents last 17 years, during which a pharmaceutical company has an exclusive right to manufacture a particular drug. After the patent expires, generic versions of the product can be produced and sold by competitors. Generic medication is cheaper to produce (due to the substantially lower research and development costs) than brand medication, and the lower cost is often a strong incentive for consumers to choose generics over branded drugs. In addition, the presence of a generic alternative may force a decrease in the brand name medication's price, through increased competition.

The generics industry itself is also facing the threat of cheaper competition. With the development of advanced drug manufacturing facilities in countries such as China, generics will likely undergo even further price cuts. China is already the world's largest supplier of raw materials for drug manufacture, but has not produced significant amounts of finished drugs for export. Last year, the FDA approved the first Chinese generic, a copy of the AIDS drug nevirapine, and another ten other Chinese companies are expected to come out with generics this year. [3]

Political pressures: pricing/licensing

Pharmaceutical companies face constant pressure from governments and activist organizations to increase access by either lowering prices substantially or granting generic licenses. Although these policies would increase the volume of sales, there would be a significant impact on total profits. However, if price controls or granting generic licenses occur, then companies will be less likely to invest money and research into new and unique medications. If this intellectual piracy occurs, less investment will occur.

Dependence on health insurance

Changes in health care coverage may impact drug sales. If an insurance program changes its policies and removes coverage for a certain treatment, sales of related drugs are likely to decrease. In general, insurance programs are more likely to cover essential expenses, such as heart disease medication, and less likely to cover nonessential expenses, such as cosmetic surgery.

Litigation risk

Pharmaceuticals can face significant liabilities if a medication is later found to be defective or produce adverse reactions. Even though such adverse reactions are previously unknown and impossible to predict, damages claimed in such lawsuits are usually substantial. Depending on jurisdiction, the legal system may limit allowable damages.

Future Growth Strategies

Drug development costs have increased significantly in the past decade due to increased FDA regulations and the desire for long term testing. The total cost and time to market for new drugs can be in the hundreds of millions of dollars and up to a decade, respectively. In addition, competition with generic drugs in emerging markets such as China and India have put pressure on drug companies' bottom lines. Despite these factors, drug companies do not prioritize cost cutting in the near future as much as other strategies for continued growth. In a recent survey of major executives at 15 large and medium drug companies, increased investment into R&D ranked first as a priority for the future, having been cited by 66% of the survey group. Cost cutting tied with expanding into new markets, as well as restructuring marketing in drawing 40% of the group (each executive was given two votes). [4]

Market Share by Region

Worldwide pharmaceutical sales increased by 8% in 2006 to £328 billion. The U.S. dominates the global demand for pharmaceutical drugs based on dollar amounts, accounting for nearly half of all sales.

Pharmaceuticals World Market Share by Region (2006) [5]

Value ($bn)* % of Total Growth vs. 2005**
USA 268.3 44% 9%
Europe 171.7 28% 6%
France 32.6 5% 4%
Germany 30.7 5% 3%
UK 20.0 3% 3%
Italy 19.4 3% 7%
Japan 57.9 10% -3%
Asia Pacific 43.1 7% 14%
Latin America 29.4 5% 21%
Middle East, Africa 20.9 3% 13%
Canada 15.4 3% 19%
Total 606.6 100% 8%

Note: *Based on an average 2006 £/$ exchange rate of 1.85 [6]

Note: **Based on £ figures from 2005; does not account for exchange rate difference between 2005 and 2006

Major Drug Manufacturers

While there are a great number of smaller publicly traded drug companies, the top firms represent the majority of the market. The following companies are each active in multiple therapeutic areas, whereas smaller firms generally specialize in a very specific product market.


Pharmaceutical and Biotech Industry — Competitive Operating Metrics (2007)

 

Johnson & Johnson (JNJ)

Pfizer (PFE)

Novartis (NVS)

Abbott Laboratories (ABT)

Merck (MRK)

Wyeth (WYE)

Bristol-Meyers Squibb (BMY)

Eli Lilly (LLY)

Amgen (AMGN)

Schering-Plough (SGP)

Boston Scientific (BSX)

Biogen Idec (BIIB)

Revenue (in billions of USD)

Total Revenue

$61.10

$48.42

$38.95

$25.91

$24.20

$22.40

$19.35

$18.63

$14.77

$12.69

$8.36

$3.17

Gross Profit

$43.34

$37.18

$27.04

$14.49

$18.06

$16.09

$13.13

$14.38

$12.22

$8.29

$6.02

$2.84

Revenue Growth from 2006

14.57%

0.10%

10.94%

15.30%

6.90%

10.07%

12.12%

18.75%

3.53%

19.78%

6.85%

18.21%

Income

Net Income

$10.58

$8.14

$11.95

$3.61

$3.28

$4.62

$2.17

$2.95

$3.17

-$1.47

-$0.50

$0.64

Net Profit Margin

17.31%

17.05%

16.79%

13.92%

13.54%

20.61%

14.12%

15.85%

21.43%

-11.61%

-5.92%

20.12%

Operating Income

$13.28

$9.28

$6.78

$4.58

$3.37

$6.46

$3.53

$3.88

$3.98

-$1.22

-$0.01

$0.78

Return on Average Equity

25.60%

12.06%

14.43%

22.66%

18.33%

28.09%

19.15%

23.96%

17.19%

-22.17%

-3.26%

10.05%

Other

Employees

119,200

86,600

98,200

68,000

59,800

50,527

42,000

40,600

17,500

55,000

27,500

4,300


Top Pharmaceutical Categories

Pharmaceuticals World Market of Top 5 Therapeutic Classes (2006) [7]

Value ($bn)* % of Total Growth vs. 2005**
Cardiovascular 100.8 17% 7%
Central nervous system 99.9 16% 8%
Alimentary tract and metabolic 73.6 12% 9%
Anti-infectives (bacterial,viral and fungal) excluding vaccines 61.4 10% 3%
Respiratory 40.1 7% 6%

Note: *Based on an average 2006 £/$ exchange rate of 1.85 [8]

Note: **Based on £ figures from 2005; does not account for exchange rate difference between 2005 and 2006

References

  1. Cowen and Company. Therapeutic Categories Outlook. March 2008.
  2. What's Ailing the Pharmaceutical Sector?.
  3. http://www.reuters.com/article/healthNews/idUSL1312745520080513?feedType=nl&feedName=ushealth1100
  4. Pharmalot. "Pharma Execs: Cost Cutting Is Not A Top Priority." 12 November 2008.
  5. GlaxoSmithKline 2006 20-F Filing, p. 26
  6. GlaxoSmithKline 2006 20-F Filing, p. 94
  7. GlaxoSmithKline 2006 20-F Filing, p. 26
  8. GlaxoSmithKline 2006 20-F Filing, p. 94


Top Ten/Twenty Best Selling Drugs 2009 http://knol.google.com/k/top-ten-twenty-best-selling-drugs-2009#

M&A Biotechnology http://knol.google.com/k/m-a-biotechnology#

http://knol.google.com/k/biotechnology-market-review-top-ten-biologics-2009#

Monoclonal Antibody Market 2009 http://knol.google.com/k/-/monoclonal-antibody-market-2009/3fy5eowy8suq3/86#

http://knol.google.com/k/new-drug-approvals-usa-fda-2009#

http://knol.google.com/k/new-drug-approvals-europe-ema-2009#

Vaccine Market 2009 http://knol.google.com/k/-/vaccine-market-2009/3fy5eowy8suq3/104#

http://knol.google.com/k/influenza-antivirals-market-2009#

Global Monoclonal Antibodies Market Review 2008 (World Top Ten mAbs) http://knol.google.com/k/global-monoclonal-antibodies-market-review-2008-world-top-ten-mabs#

M&A Review: Pharmaceutical & Biotechnology Industry http://knol.google.com/k/m-a-review-pharmaceutical-biotechnology-industry#

Global Vaccine Market Review 2008 (World Top Ten Vaccines) http://knol.google.com/k/global-vaccine-market-review-2008-world-top-ten-vaccines#

Global Pharmaceutical Market Review & World Top Ten/Twenty Drugs 2008 http://knol.google.com/k/global-pharmaceutical-market-review-world-top-ten-twenty-drugs-2008#

http://knol.google.com/k/global-market-intelligence-overview-monograph-2009#

http://knol.google.com/k/global-cardiovascular-market-review-2008-world-top-ten-cv-drugs#

http://knol.google.com/k/global-cancer-market-review-2008-world-top-ten-cancer-drugs#

http://knol.google.com/k/global-brain-drugs-market-review-2008-world-top-ten-cns-drugs#

http://knol.google.com/k/global-arthritis-market-review-2008-world-top-ten-ra-drugs#

http://knol.google.com/k/billion-dollar-generics-global-generic-market-review-2009#

http://knol.google.com/k/global-angiotensin-ii-receptor-antagonists-market-review-2008#

http://knol.google.com/k/global-antiviral-antibiotics-market-review-2008-world-top-ten-antimicrobial#

http://knol.google.com/k/global-diabetes-market-review-2008-world-top-ten-diabetes-drugs#

http://knol.google.com/k/global-respiratory-market-review-world-top-ten-respiratory-drugs-2008#

http://knol.google.com/k/global-pharmaceutical-market-intelligence-monograph#



Ipilimumab (BMS) Review: A Cancer Breakthrough? http://knol.google.com/k/-/ipilimumab-bms-review-a-cancer/3fy5eowy8suq3/107#

Denosumab (Prolia, Amgen) FDA Review & Approval http://knol.google.com/k/-/denosumab-prolia-amgen-fda-review/3fy5eowy8suq3/60#

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki